Clinical outcome of established diagnostic and treatment modalities of COVID-19-associated myocarditis : a systematic review

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc..

Despite the significant research and development of COVID-19 diagnostic and therapeutic approaches, the virus still poses a concern, particularly to groups that are already vulnerable. Several individuals experienced cardiac problems like myocardial infarction, arrhythmia, heart failure, cardiomyopathy, myocarditis, and pericarditis after they had recovered from the infection. Early diagnosis and timely management of sequelae are part of the therapy. However, there are gaps in the knowledge of the diagnostic and definitive treatment options for COVID-19 myocarditis. This review focuses on myocarditis associated with COVID-19.

Objective: This systemic review provides the most recent overview of myocarditis caused by COVID-19, including clinical manifestations, diagnostic techniques, available treatments, and outcomes.

Methods: The PubMed, Google Scholar, and ScienceDirect servers were used to conduct a systematic search in compliance with the PRISMA guidelines. Boolean search terms included "(COVID-19)" OR "(COVID19)" OR "(COVID-19 VIRUS INFECTION)" AND "(MYOCARDITIS)". The results were tabulated and analyzed.

Results: A total of 32 studies, including 26 case reports and 6 case series, were included in the final analysis, and 38 cases of COVID-19-associated myocarditis were analyzed. Middle-aged men constituted the most affected population (60.52%). Dyspnoea (63.15%), chest pain or discomfort (44.73%), and fever (42.10%) were the prevalent presentations. ST-segment abnormalities were reported in 48.38% of cases on electrocardiography testing. Leucocytic infiltration (60%) was the frequent finding obtained on endomyocardial biopsy. Cardiac magnetic resonance imaging yielded myocardial oedema (63.63%), and late gadolinium enhancement (54.54%) as the most common findings. Reduced ejection fraction (75%) was the frequent result obtained on echocardiography. Corticosteroids (76.31%) and immunomodulators (42.10%) were the well-established in-hospital medications. Veno-arterial extracorporeal membrane oxygenation (35%) was the most common intervention used to support the treatment. The frequent in-hospital complications were cardiogenic shock (30.76%), followed by pneumonia (23.07%). The mortality rate was 7.9%.

Conclusion: Early detection and timely management of myocarditis are essential to reduce the risk of developing further complications. It is crucial to emphasize the need to evaluate COVID-19 as a possible cause of myocarditis in populations that are young and healthy to avoid fatal consequences.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:85
Enthalten in:	Annals of medicine and surgery (2012) - 85(2023), 7 vom: 30. Juli, Seite 3583-3594

Sprache:	Englisch

Beteiligte Personen:	Sai Santhosha Mrudula, Alla [VerfasserIn] Agarwal, Pahel [VerfasserIn] Vempati, Roopeessh [VerfasserIn] Alla, Deekshitha [VerfasserIn] Balusu, Kavya [VerfasserIn] Tarannum, Suha [VerfasserIn] Patel, Krish [VerfasserIn] Devaragudi, Sanjana [VerfasserIn] Patel, Devkumar [VerfasserIn] Sultana, Qamar [VerfasserIn] Paudel, Kusum [VerfasserIn]

Links:	Volltext

Themen:	COVID-19 Cardiac magnetic resonance imaging Echocardiography Endomyocardial biopsy Journal Article Myocarditis Steroids

Anmerkungen:	Date Revised 18.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE

doi:	10.1097/MS9.0000000000000964

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM359282334